Date: 2014-06-11
Type of information: Presentation of results at a congress
phase:
Announcement: presentation of results at the EULAR Annual European Congress of Rheumatology held in Paris on June 11-14, 2014.
Company: Active Biotech (Sweden)
Product: paquinimod (57-57)
Action
mechanism: Paquinimod is a quinoline compound primarily intended for the treatment of systemic sclerosis. This rare disease is classified as an orphan drug indication. In 2011 and 2014, paquinimod was granted orphan medicinal product status in Europe and US for the indication systemic sclerosis.
Disease: systemic sclerosis
Therapeutic area: Rare diseases
Country:
Trial details:
Latest
news: * On June 11, 2014, Active Biotech announced that it will present data related to the drug candidate paquinimod (57-57) for the treatment of systemic sclerosis, at the scientific conference \"EULAR Annual European Congress of Rheumatology\" held in Paris on June 11-14, 2014. These presentations include: - (FRI0496) An open-label study to evaluate biomarkers and safety in systemic sclerosis (SSc) patients treated with paquinimod (ABR-215757). Hesselstrand R., Distler J.H., Riemekasten G., Törngren M., Nyhlén H. C., Stenström M., Andersson F., Eriksson H., Sparre B., Tuvesson H., Distler O. In this study, nine patients were treated with paquinimod 3 mg/day for eight weeks. The primary endpoint of the study was changes in disease related biomarkers. Paquinimod was well tolerated and effects on biomarkers relevant for SSc were observed during treatment. - (FRI0516) Paquinimod (ABR-215757), an immunomodulatory compound, reduces fibrosis in the tight-skin 1 (TSK-1) model for systemic sclerosis. Stenström M., Nyhlén H. C., Nilsson M., Eriksson H., Törngren M., Distler J.H., Distler O., Sparre B., Tuvesson H. The purpose of this pre-clinical study was to investigate the effects of paquinimod in an experimental disease model for systemic sclerosis. The results show that paquinimod reduces development of skin fibrosis in this disease model.
